GlassScriptPhysician profile
Dijana Jefic
NPI 1730134057
$5,096.45
in general payments reported to CMS, 2019-2025
23 companies · $963 in 2025
The $963 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $192 · 2021: $428 · 2022: $596 · 2023: $1,746 · 2024: $1,060 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695 · Education: $73.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,695.33 |
| Education | $73.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,048.82 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $775.66 | 2021-2025 | |
| Akebia Therapeutics INC | $404.89 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $374.02 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $363.73 | 2022-2024 | Tarpeyo |
| Horizon Therapeutics Plc | $357.60 | 2022-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $251.00 | 2022-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $250.57 | 2022-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $231.35 | 2023-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $191.82 | 2021-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $186.57 | 2021-2025 | Benlysta, Jesduvroq, Arexvy |
| Baxter Healthcare | $149.98 | 2024 | Perclot |
| Mallinckrodt Hospital Products INC. | $83.89 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $83.25 | 2023-2025 | |
| Boston Scientific Corporation | $82.60 | 2019-2025 | General - Pain Management |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $76.04 | 2023-2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $47.11 | 2024 | Velphoro |
| Novo Nordisk INC | $30.26 | 2022-2024 | Rybelsus, Ozempic |
| Amgen INC. | $25.32 | 2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $25.06 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.79 | 2023 | Jardiance |
| Azurity Pharmaceuticals, INC. | $18.57 | 2025 | Edarbi |
| Alexion Pharmaceuticals, INC. | $18.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dijana Jefic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.